ThermoGenesis Holdings Inc. (NASDAQ: (THMO) stock declined by 1.09% at the last close whereas the THMO stock price remained unchanged in the pre-market trading session. ThermoGenesis Holdings creates, licenses, and sells automated technology for CAR-T and other cell-based treatments. The company now offers a comprehensive suite of automated clinical biobanking, point-of-care apps, and immuno-oncology automation solutions.
THMO stock’ Recent Past Development
ThermoGenesis Holdings has been granted a $250,000 Phase I SBIR grant to research and develop the single-use sterile cell processing disposable that will be utilized by the fully automated Quintessence System. These programs enable US-owned life science firms to participate in government research and development with a high potential for commercialization that aligns with the NIH’s goal to improve health and save lives. 15 granted patents and 13 pending applications cover this technique.
Existing X-Series cartridges have been shown to concentrate mononuclear cells from blood with 90-100 percent target cell recovery rates (for T cells and hematopoietic stem cells). It’s also possible to wash or volume-reduce cell solutions with the same level of success. Additionally, X-BACS reagents found in X-Series cartridges are up to 50% more efficient than traditional ferrous bead/magnetic field techniques for high-purity target cell separation. In comparison to traditional methods, these advances can provide a 6-fold increase in cell output. Target blood cells generated in this manner have been demonstrated to be just as easily transduced with lentiviral vectors as traditionally manufactured target cells.
Furthermore,
The following are the specific goals of this grant:
- Prototype and small-batch manufacturing of an upgraded X-Series cartridge with extra capabilities needed to support the Aim.
- The goal for application for a Phase 2 SBIR to build and verify the Quintessence instrument that would completely automate that process is to validate and optimize the performance of all phases of GEAC production in a single such cartridge (‘one-pot’ workflow).
